Dainippon granted Takeda exclusive rights to develop and commercialize lurasidone for schizophrenia and bipolar disorder in the EU, Switzerland, Norway, Turkey and Russia

Dainippon Sumitomo Pharma Co. Ltd.

Japan / Mid-Cap Biopharma ($1-$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Takeda Pharmaceutical Co. Ltd.

Japan / Mid-Cap Biopharma ($1-$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Terminated

Sample

01/01/2009

announced

01/01/2009

Terminated